Further, the data acquired in this research presented the preliminary proof for SLIT3/UBE2C/WNT signaling pathway on lung cancer development and progression, providing novel insight and strategy in clinical NSCLC treatment. Here, UBE2C is linked to non-small cell lung carcinoma.